소세포 폐암에서 Cisplatin과 Etoposide (VPP) 복합화학요법의 효과 = Cisplatin and Etoposide (VPP) Combination Chemotherapy in Small Cell Lung Cancer

다국어 초록 (Multilingual Abstract)

Background : Reports of the result of cisplatin plus VP-16(VPP) combination as second line therapy following cyclophosphamide, doxorubicin, vincristine (CAV) suggested that VPP might be non-cross resistant with the CAV regimen. We evaluated the efficancy and toxicity of VPP combination therapy as a first line therapy for small cell lung cancer (SCLD). Methods : Fifty-one patients with SCLC were treated with cisplatin (20mg/㎡ i.v., X 5 days) and etoposide (100mg/㎡ i.v., X 3 days) every three weeks. In patients with limited disease. radiation to primary site was performed after 3rd cycle VPP. Results : 1) Among the 51 treated patients, 45 were evaluated for response to VPP chemotherapy. Complete response rate was 18.6%, and partial response rate was 51.2%. 2) The median overall survival was 51 weeks. The median survival was 59 weeks in limited disease, and 50 weeks in extensive disease. There was no significant difference between the two groups. 3) The median time to progression was 51 weeks in responder. 4) The toxicities were mild to moderate degree ; anorexia, nausea and alopecia in most cases, neurotoxicities in 23.8% and nephrotoxicities in 21.4%. Leukopenia (66.7%) and thrombocytopenia (13.5%) were not severe. Conclusion : VPP combination therapy was effective in small cell lung cancer as first line chemotherapy.